Tag: Nirsevimab
-
Nirsevimab sharply reduces RSV hospitalizations in U.S. infants during 2024-2025 season
Real-world data show strong protection for U.S. infants As the United States navigates the 2024-2025 RSV season, several U.S. health networks published real-world analyses underscoring the protective effect of nirsevimab in infants. Across multiple settings, infants who received the preventive monoclonal antibody before RSV circulation experienced markedly lower rates of RSV-related hospitalizations compared with comparable…
-
Nirsevimab Slashes RSV Hospitalizations in US Infants During 2024-2025
Real‑world data show strong protection for US infants A recent research letter analyzing the 2024‑2025 RSV season indicates that administering nirsevimab to infants is associated with fewer hospitalizations due to RSV. While randomized trials proved safety and efficacy, real‑world data confirm that protection extends into everyday clinical practice, easing bed occupancy and the caregiving burden…
-
Nirsevimab Reduces RSV Hospitalizations in US Infants During 2024-25 Season
Overview New real‑world data from the 2024-2025 RSV season indicate that nirsevimab, a monoclonal antibody given to infants to prevent severe respiratory syncytial virus (RSV) infection, provides powerful protection. In a recent research letter analyzing administration patterns and hospitalizations, researchers report a clear reduction in RSV-related hospital stays among U.S. infants who received nirsevimab compared…